Célèste Lebbé
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Immunotherapy and Immune Responses
Most-Cited Works
- → Improved Survival with Ipilimumab in Patients with Metastatic Melanoma(2010)15,035 cited
- → Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation(2011)7,653 cited
- → Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
- → Nivolumab in Previously Untreated Melanoma without BRAF Mutation(2014)5,311 cited
- → Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma(2011)4,451 cited
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria(2009)3,202 cited
- → Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma(2017)2,174 cited
- → Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma(2014)1,843 cited
- → Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial(2015)1,372 cited